Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 0.69 |
| ▸ | HTR1A | P08908 | 7/20 | 0.69 |
| ▸ | HTR2A | P28223 | 7/20 | 0.69 |
| ▸ | DRD4 | P21917 | 3/20 | 0.63 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533757 | 0.99 | DRD3 (1.00) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL4524712 | 0.82 | KCNH2 (0.70) | DRD3KCNH2DRD2HTR1AHTR7 | |
| SCHEMBL5379573 | 0.82 | DRD2 (1.00) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL15546332 | 0.78 | DRD2 (0.74) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL4244520 | 0.78 | DRD2 (0.67) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL4523316 | 0.78 | KCNH2 (0.64) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL4529646 | 0.78 | KCNH2 (0.68) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL5826339 | 0.78 | DRD3 (0.65) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL15532889 | 0.78 | DRD2 (0.65) | DRD3KCNH2DRD2HTR1AHTR2A | |
| SCHEMBL3606509 | 0.78 | DRD3 (1.00) | DRD3KCNH2DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | DRD3 10/4885KCNH2 769/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.